Lartruvo (olaratumab) is given as an intravenous infusion on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity. Lartruvo injection is used in combination with doxorubicin for the treatment of adult patients with soft tissue sarcoma (STS) who cannot be cured with radiation or surgery.